Drug · CHEMBL911
ZOLPIDEM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ZOLPIDEM. Drugs and targets, record CHEMBL911. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL911
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GABRA1 | GABA A receptor alpha-1/beta-1/gamma-2 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2554 |
| GABRB1 | GABA A receptor alpha-1/beta-1/gamma-2 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2560 |
| GABRG2 | GABA A receptor alpha-1/beta-1/gamma-2 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2566 |
Source ChEMBL
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials118
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00608985 | Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia | Phase 3 | 709 | 2013-02-07 | zolpidem | Its name | ClinicalTrials.gov |
| NCT00784875 | An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia | Phase 2 | 643 | 2012-02-29 | zolpidem | Its name | ClinicalTrials.gov |
| NCT03375203 | A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder | Phase 2 | 365 | 2022-05-23 | zolpidem | Its name | ClinicalTrials.gov |
| NCT02839200 | Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder | Phase 2 | 360 | 2020-04-02 | zolpidem | Its name | ClinicalTrials.gov |
| NCT01651442 | Sequenced Therapies for Comorbid and Primary Insomnias | 211 | 2019-08-28 | zolpidem | Its name | ClinicalTrials.gov | |
| NCT03774810 | Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia | Phase 4 | 197 | 2025-05-09 | zolpidem | Its name | ClinicalTrials.gov |
| NCT04468776 | CBT-I or Zolpidem/Trazodone for Insomnia | Phase 4 | 155 | 2025-02-24 | zolpidem | Its name | ClinicalTrials.gov |
| NCT00492232 | Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia | Phase 4 | 135 | 2009-07-17 | zolpidem | Its name | ClinicalTrials.gov |
| NCT00662155 | The Role of Partial Reinforcement in the Long Term Management of Insomnia | 129 | 2017-08-07 | zolpidem | Its name | ClinicalTrials.gov | |
| NCT01685073 | The Role of Sleep in the Treatment of Cannabis Use Disorders | Phase 2/3 | 127 | 2019-05-22 | zolpidem | Its name | ClinicalTrials.gov |
1 to 10 of 118
See all 118 trialsComparisons in its trials29
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ramelteon 8 mg QD vs Placebo QD: Participants Who Achieved a 50% Reduction in Zolpidem Dosage at Any Time During the Double-Blind Treatment Period | 50 of 64 | 50 of 70 | 134 | NCT00492232 | Trial comparisons |
| Ramelteon 8 mg QD vs Placebo QD: serious adverse events | 0 of 64 | 1 of 70 | 134 | NCT00492232 | Trial comparisons |
| Zolpidem vs Placebo: deaths from any cause | 0 of 62 | 0 of 65 | 127 | NCT01685073 | Trial comparisons |
| Zolpidem vs Placebo: serious adverse events | 2 of 62 | 0 of 65 | 127 | NCT01685073 | Trial comparisons |
| Zolpidem-CR vs Placebo: deaths from any cause | 0 of 51 | 0 of 52 | 103 | NCT01689909 | Trial comparisons |
| Zolpidem-CR vs Placebo: serious adverse events | 1 of 51 | 0 of 52 | 103 | NCT01689909 | Trial comparisons |
| Ramelteon 8 mg QD vs Placebo QD: Participants Who Achieved a 50% Reduction in Zolpidem Dosage at the End of the Double-Blind Treatment Period | 48 of 52 | 42 of 49 | 101 | NCT00492232 | Trial comparisons |
| Medication (Zolpidem or Trazodone) vs Combination: Medication Adherence | 38 of 45 | 28 of 44 | 89 | NCT04468776 | Trial comparisons |
| Midazolam vs Zolpidem: deaths from any cause | 0 of 38 | 0 of 42 | 80 | NCT02096900 | Trial comparisons |
| Midazolam vs Zolpidem: serious adverse events | 0 of 38 | 0 of 42 | 80 | NCT02096900 | Trial comparisons |
1 to 10 of 29
See all 29 comparisons in its trialsPapers from its trials78
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials16
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Symbol Coding | 7 | 2 | ConductCognition |
| Psychomotor Vigilance Task | 6 | 3 | ConductCognition |
| Choice Reaction Time | 4 | 1 | ConductCognition |
| Delayed Recall Module | 2 | 0 | ConductCognition |
| 1-Back Task | 2 | 0 | ConductCognition |
| Simple Reaction Time | 2 | 0 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Free Recall Task | 1 | 0 | ConductCognition |
| Go/No-Go Association Task | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
1 to 10 of 16
See all 16 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL911
GET https://conductscience.org/api/drugs/v1/CHEMBL911/trials?page=2